Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 10—October 2024
Dispatch

Mpox Epidemiology and Vaccine Effectiveness, England, 2023

Hannah CharlesComments to Author , Katie Thorley, Charlie Turner, Kirsty F. Bennet, Nick Andrews, Marta Bertran, Sema Mandal, Gayatri Amirthalingam, Mary E. Ramsay, Hamish Mohammed, and Katy Sinka
Author affiliation: UK Health Security Agency, London, UK

Main Article

Table 1

Available demographic characteristics of mpox case-patients, England, 2022 and 2023*

Variable Year, no, (%)
2022, n = 3,412† 2023, n = 137
Region
London 2,359 (69) 105 (77.0)
Outside London 1,040 (30) 32 (23.0)
Unknown
 13 (0.4)
 0
Sex
M 3,345 (98) 135 (99.0)
F 45 (1.3) 1 (0.7)
Unknown
 22 (0.6)
 1 (0.7)
Sexual orientation GBMSM 983 (97)‡ 128 (93)§ 

*Patients were median 36 years of age for both years (IQR 30–44 y in 2022 and 29–43 y in 2023). IQR, interquartile range; GBMSM, gay, bisexual, and other men who have sex with men. †May 6–Sep 16, 2022 (1). ‡Obtained via enhanced surveillance questionnaires, which were complete for 31% of case-patients by September 18, 2022. §107 case-patients self-identified identifying as GBMSM plus 21 who were adult men without recorded information on sexual orientation and no travel to mpox-endemic countries in Central or West Africa but were presumed to be part of the outbreak.

Main Article

References
  1. UK Health Security Agency. Monkeypox outbreak: technical briefing 8 [cited 2024 Feb 14]. https://www.gov.uk/government/publications/monkeypox-outbreak-technical-briefings/investigation-into-monkeypox-outbreak-in-england-technical-briefing-8
  2. UK Health Security Agency. Mpox (monkeypox) outbreak: epidemiological overview [cited 2024 Feb 14]. https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-overview
  3. UK Health Security Agency. Mpox (monkeypox): case definitions [cited 2024 Feb 14]. https://www.gov.uk/guidance/monkeypox-case-definitions
  4. UK Health Security Agency. Reporting to UKHSA: a guide for diagnostic laboratories [cited 2024 Feb 14]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1159953/UKHSA_Laboratory_reporting_guidelines_May_2023.pdf
  5. UK Health Security Agency. Notifiable diseases and causative organisms: how to report [cited 2024 Feb 14]. https://www.gov.uk/guidance/notifiable-diseases-and-causative-organisms-how-to-report
  6. Flannery  B, Andrews  N, Feikin  D, Patel  MK. Commentary: Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 2023;52:19–21. DOIPubMedGoogle Scholar
  7. Bertran  M, Andrews  N, Davison  C, Dugbazah  B, Boateng  J, Lunt  R, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis. 2023;23:828–35. DOIPubMedGoogle Scholar
  8. UK Health Security Agency. HIV action plan monitoring and evaluation framework [cited 2024 Apr 25]. https://www.gov.uk/government/publications/hiv-monitoring-and-evaluation-framework
  9. Chicago Health Alert Network. Potential risk for new mpox cases—provider update: May 9, 2023 [cited 2024 Feb 14]. https://emergency.cdc.gov/han/2023/han00490.asp
  10. Chicago Department of Public Health. Mpox dashboard [cited 2024 Feb 14]. https://www.chicago.gov/city/en/depts/cdph/provdrs/infectious_disease/supp_info/mpox-home/mpox-dashboard.html
  11. Hazra  A, Zucker  J, Bell  E, Flores  J, Gordon  L, Mitjà  O, et al. Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect Dis. 2023.
  12. World Health Organization. Multi-country outbreak of mpox: external situation report #31—22 December 2023 [cited 2024 Feb 14]. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-31---22-december-2023

Main Article

Page created: August 27, 2024
Page updated: September 23, 2024
Page reviewed: September 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external